REMS

A REMS (Risk Evaluation and Mitigation Strategy) is an FDA-required safety program under 21 USC 355-1 imposed on certain prescription drugs where the FDA has determined that the drug's safety profile requires risk management beyond the labeling. REMS programs may require prescriber certification, pharmacy certification, patient enrollment, periodic safety reporting, and Elements to Assure Safe Use (ETASU) restrictions on dispensing. Common REMS-restricted drug classes include certain opioids, clozapine, isotretinoin, and various oncology and biologic preparations.

How REMS works

For each drug subject to a REMS, FDA approves a specific program with defined elements. ETASU programs commonly include: prescriber enrollment and certification (CE, attestation, registration with the REMS administrator); pharmacy enrollment, certification, and recertification on a defined cadence; patient enrollment, informed consent, and lab monitoring requirements; periodic safety reporting from prescribers and pharmacies; and dispensing restrictions (controlled distribution, single-source distribution, or specific dispensing protocols).

Pharmacy compliance with REMS is audited by the REMS administrator (typically a third party retained by the manufacturer under FDA-approved REMS terms) and by FDA. A REMS audit finding can result in pharmacy decertification, which ends the pharmacy's ability to dispense the REMS-restricted drug. Significant or repeated REMS violations can also support FDA enforcement under the Federal Food, Drug, and Cosmetic Act, including misbranding and adulteration theories where the dispensing did not comply with the REMS-approved framework.

When REMS applies

REMS applies to every prescription, dispense, and patient enrollment for a REMS-restricted drug. Specialty pharmacies handle most REMS-restricted dispensing because the certification and infrastructure requirements concentrate the dispensing pattern in pharmacies with the operational capability. PBM audits commonly include REMS compliance verification on the relevant drug classes; PBM findings of REMS noncompliance can support recoupment and network discipline.

The pharmacy's exposure under REMS

Decertification is the most acute REMS exposure: a decertified pharmacy can no longer dispense the affected drug. Where the pharmacy's specialty book concentrates in REMS-restricted drugs, decertification ends the relevant business line. PBM recoupment exposure runs on top: PBM audits can identify REMS noncompliance and convert it into a recoupment demand for the affected claims. FDA enforcement exposure runs through the FDC Act framework where the violations are substantial. The defense framework focuses on REMS recertification, contemporaneous compliance documentation, audit-finding challenge on the procedural compliance record, and coordination between FDA and PBM tracks where they overlap.

Related terms

• GLP-1 The drug class that intersects with REMS in certain dispensing contexts.
• Specialty pharmacy The pharmacy category that handles most REMS-restricted dispensing.
• Limited Distribution Drug The distribution restriction framework that often accompanies REMS programs.
• Prior authorization The PBM-side approval process that runs alongside REMS dispensing requirements.

See also

• Practice area
  Specialty Pharmacy Audit Defense

  The full specialty pharmacy defense framework spanning REMS compliance, LDD networks, and PBM audit response.

• Practice area
  PBM Audit Defense

  PBM audit defense framework including REMS-related findings response.

• Practice area
  FDA Warning Letter Response

  Defense framework for FDA enforcement that pivots on REMS noncompliance.